SMMT
Summit TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
SMMT vs peer average
40/100
SMMT vs. peer average (D vs. C)
Grade spread
A 1 · B 2 · C 3 · D 2 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
MRK is the first available peer comparator.
Direct NSCLC immuno-oncology comparator because Summit's HARMONi-3 is designed against pembrolizumab plus chemotherapy, while Summit's 10-K also identifies Merck's sacituzumab tirumotecan among Phase III competitive candidates in first-line NSCLC [#10-K-2026-02-23].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SMMT
Summit Therapeutics
MRK
Merck
Grade
D
C
Momentum
36
82
Value
41
62
Sentiment
54
53
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs MRK
SMMT / MRK
Grade Position
Below peers
SMMT vs. peer average (D vs. C)
40/100
Momentum
36
MRKValue
41
MRKSentiment
54
SMMTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SMMT
MRK is the first peer returned for this comparison set.